444P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
Han Li(Hebei Medical University), Zhenfeng Shi(Shandong First Medical University), G. ren(Chongqing Technology and Business University), Dejun Zhou(Henan Polytechnic University), Baoquan Zhang(Tianjin University), Xun Sun(Tianjin Hospital), Z. Yv(Binzhou Medical University), Bo Fan(Sichuan University), Xiaochen Zhao, Shengrong Sun(Wuhan University), Zhaoyang Wang(Binzhou Medical University), Xiangyu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Li(University of California, Los Angeles), Weiling Li(Shandong University), Jing Huang(Nanchang University), Haiying Fu(Jilin University), Yiqiu Liao(Nanchang University)
Cited by 1
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Human infection of avian influenza A H3N8 virus and the viral origins: a descriptive study
|The Lancet Microbe|2022|176
Chemical Stability and Its Improvement of Palladium-Based Metallic Membranes
|Industrial & Engineering Chemistry Research|2004|173
Blood Pressure Changes and Chemical Constituents of Particulate Air Pollution: Results from the Healthy Volunteer Natural Relocation (HVNR) Study
|Environmental Health Perspectives|2012|166